CN Patent

CN104470923A — 选择性PI3K δ抑制剂

Assigned to Rhizen Pharmaceuticals AG · Expires 2015-03-25 · 11y expired

What this patent protects

本发明涉及具有1H-吡唑并[3，4-d]嘧啶环系统的PI3Kδ蛋白激酶的选择性抑制剂，制备它们的方法，包含它们的药物组合物和利用它们治疗和/或预防激酶介导的相关疾病或病症的方法。

USPTO Abstract

本发明涉及具有1H-吡唑并[3，4-d]嘧啶环系统的PI3Kδ蛋白激酶的选择性抑制剂，制备它们的方法，包含它们的药物组合物和利用它们治疗和/或预防激酶介导的相关疾病或病症的方法。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN104470923A
Jurisdiction: CN
Classification: —
Expires: 2015-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.